Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx

5

XVII.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

3
Last update : 13/03/2022
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Atezolizumab
2
Avelumab
1
CTLA4 blocking immunotherapy
3
Camrelizumab
1
Ipilimumab
4
Lambrolizumab
4
Nivolumab
5
PD-1/PD-L1-inhibitors or blocking agents/drugs
5
Pedelizumab
1
Pembrolizumab
5
Tislelizumab
1
Tremelimumab
1
Vaccination - Immunization
2
Vaccines
3
Zimberelimab
1

Publications

Pulmonary tuberculosis associated with immune checkpoint inhibitors: a pharmacovigilance study.
Thorax 2022 Jul;77;721-723 2022 Jul
Pleural Effusion Occurring During Lung Cancer Immunotherapy: A Challenge for the Clinician.
Archivos de bronconeumologia 2022 Feb;58;194-196 2022 Feb
Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy.
Internal medicine (Tokyo, Japan) 2021 Jun 01;60;1743-1746 2021 Jun 01
Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2018 Mar;24;216-218 2018 Mar
Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition.
American journal of respiratory and critical care medicine 2018 Dec 01;198;1451-1453 2018 Dec 01
Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer.
Acta oncologica (Stockholm, Sweden) 2018 Aug;57;1127-1128 2018 Aug
Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Dec;11;2048-2050 2016 Dec
Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Dec;11;2238-2240 2016 Dec

Powered by

  • ^
  • Contact
  • Cookies
  • About